

Prof.Dr.Hubert Caron is head of the pediatric oncology center in the AMC, Amsterdam, Netherlands. He is a pediatric oncologist with a long clinical experience in treating children with cancer. His main clinical interests are children with solid tumors, especially neuroblastoma. His main research interests are evidence-based medicine, (early) clinical trials, new drug development and tumor biology and late effects.

He founded the Cochrane Childhood Cancer Review Group, which is hosted by his department. He is an active member of the Editorial board and involved in several systematic reviews.

He is involved in several clinical trials in childhood cancer and is leading the Dutch NB2009 trial for children with neuroblastoma. He chairs the DCOG early clinical trial group and is an executive member of the European early clinical trial network for childhood oncology; ITCC ('Innovative Treatments for Children with Cancer'). He is actively involved in phase 1/2 trials for children with cancer. In ITCC he chairs the biology consortium for pre-clinical evaluation of targeted cancer drugs in pediatric cancer models.

In the AMC he is PI for several tumor-biology driven pre-clinical translational research projects, aimed at improving therapy and risk-stratification of childhood neuroblastoma.

He established a very active 'late effect' research group in his department, which is leading the national DCOG-LATER programme, aimed at understanding health conditions in childhood cancer survivors based on treatment-related and constitutional risk factors.

His most recent research project involves the realization of personalized therapy for incurable high-risk childhood cancer patients with molecularly targeted agents with a mechanism-of-action matching the tumor-driving genomic aberrations of an individual child's tumor.